Ananya Choudhury

About

Professor Ananya Choudhury is Chair of Clinical Oncology and Clinical Lead for Advanced Radiotherapy within the Division of Cancer Sciences, University of Manchester as well as Honorary Consultant in Clinical Oncology at The Christie NHS Trust, UK.
Professor Choudhury undertakes research which aims to optimise and personalise radiotherapy using new techniques or imaging technology to deliver high doses of radiotherapy while minimising side effects and predictive biomarkers to determine which patients benefit from different treatments.
Professor Choudhury holds national leadership roles within the Royal College of Radiologists, and works closely with the National Institute of Health and Care Excellence (NICE). Professor Choudhury is currently the Editor in Chief of BMJ Oncology.

Employment

• The University of Manchester

Education

• Royal College of Physicians MRCP
  2000 - Present
• University of Leeds PhD Medical Sciences
  ? - 2008
• Royal College of Radiologists FRCR
  ? - 2004
• University of Cambridge MA (Cantab)
  ? - 1997
• University of Cambridge MB BChir
  ? - 1995
• University of Cambridge BA (Hon) Pharmacology
  ? - 1993

Projects & Funding

Projects & funding information is unavailable.

Publications (252)

• Circadian Genotypes in PER3 and Time of Prostate Cancer Radiotherapy Interact to Affect Risk of Late Side Effects
  Clinical Cancer Research 2026 DOI: 10.1158/1078-0432.CCR-26-0268
  +Save
• Prediction of Side Effects from Breast Radiation Therapy – Integration of Clinical and Genomic Data
  International Journal of Radiation: Oncology - Biology - Physics 2026 DOI: 10.1016/j.ijrobp.2026.08.026
  +Save
• Using biomaterial-based 3D in vitro cancer models to solve current clinical problems
  British Journal of Cancer 2026 DOI: 10.1038/s41416-026-03392-3
  +Save
• MR guided uncertainty quantification of tumour motion in open face masks versus closed face masks in head and neck radiotherapy
  Journal of Medical Imaging and Radiation Sciences 2026 DOI: 10.1016/j.jmir.2026.102196
  +Save
• Reirradiation Options for Previously Irradiated Prostate Cancer
  Clinical Oncology 2026 DOI: 10.1016/j.clon.2026.104085
  +Save
• The hypoxic ECM and neutrophils in MIBC immunotherapy resistance
  Nature Reviews Urology 2026 DOI: 10.1038/s41585-025-01092-w
  +Save
• A causal analysis of muscle characteristics and overall survival in radically treated bladder cancer patients
  2026 DOI: 10.2139/ssrn.7266767
  +Save
• Data from Integration of Dose Surface Maps and Genetic Data Identifies the Lower Posterior Rectum as a Key Region for Toxicity after Prostate Cancer Radiotherapy
  2025 DOI: 10.1158/1078-0432.c.8176710
  +Save
• Integration of Dose Surface Maps and Genetic Data Identifies the Lower Posterior Rectum as a Key Region for Toxicity after Prostate Cancer Radiotherapy
  Clinical Cancer Research 2025 DOI: 10.1158/1078-0432.CCR-25-2102
  +Save
• Supplementary Data 1 from Integration of Dose Surface Maps and Genetic Data Identifies the Lower Posterior Rectum as a Key Region for Toxicity after Prostate Cancer Radiotherapy
  2025 DOI: 10.1158/1078-0432.30750120
  +Save